Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Farletuzumab Ecteribulin · MORAb-202, BMS-986445

Antibody-drug conjugate · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by BRISTOL MYERS SQUIBB

Phase 2 Most advanced trial (none active)
BMY Developer

What is Farletuzumab Ecteribulin?

Farletuzumab ecteribulin is an antibody drug conjugate made of a humanized IgG1 antibody against folate receptor alpha, linked by a cathepsin B-cleavable linker to the microtubule inhibitor eribulin. After binding and internalization by FRA-expressing cells, eribulin is released, inhibits tubulin polymerization and causes G2/M arrest and tumor cell death. It is studied in ovarian neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MORAb-202, BMS-986445
Drug type
Antibody-drug conjugate
Targets
folate receptor alpha (FOLR1), tubulin (secondary target)
Mechanism
Cytotoxic, directed at folate receptor alpha (FOLR1)
Pathways
microtubule assembly inhibition, G2/M cell cycle arrest, mitotic spindle assembly inhibition
Therapy area
Oncology
Developer
BRISTOL MYERS SQUIBB (BMY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
UVG3B5TZN3

Conditions studied

Neoplasms, Ovarian

Other drugs acting on FOLR1

More from BRISTOL MYERS SQUIBB

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Farletuzumab Ecteribulin

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.